|
Dec 12
|
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks
|
|
Sep 23
|
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
|
|
May 29
|
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
|
|
May 22
|
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company
|
|
May 10
|
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
|
|
May 9
|
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 24
|
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 15
|
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Apr 11
|
Black Diamond Therapeutics Announces Changes to Board of Directors
|
|
Apr 8
|
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
|
|
Apr 7
|
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
|
|
Apr 3
|
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
|
|
Mar 22
|
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
|
|
Mar 14
|
Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...
|
|
Mar 12
|
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 5
|
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
|
|
Feb 28
|
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
|
|
Jan 15
|
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
|
|
Dec 5
|
With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backing
|
|
Oct 4
|
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|